One phase II clinical trial (NCT00012467) suggested that IFN-γ may provide rapid and early sterilization of CNS in patients with HIV-associated cryptococcal meningitis without pronounced adverse effects [48]. The gene discussed is IFNG; the disease is Cryptococcal meningitis.